On October 21, GlaxoSmithKline PLC rose 3.21% in Regular Trading, trading near $51.00, with turnover of $194 million.

The main catalyst was an FDA accelerated approval for Jemperli to treat certain patients with locally advanced rectal cancer, a regulatory development that strengthened sentiment around the company’s oncology pipeline.

The approval covers patients with mismatch repair-deficient or microsatellite instability-high tumors. It was supported by interim phase 2 data showing no detectable signs of cancer after treatment in all evaluated patients, while 93% remained cancer-free for at least 12 months. The update also suggests some patients may avoid chemotherapy, radiation, and surgery. In recent months, GlaxoSmithKline PLC has also reported additional oncology progress, including positive lung cancer trial updates, reinforcing broader pipeline momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)